Core Viewpoint - The stock of Insilico Medicine (03696) has risen over 7%, reaching a new high of 61.3 HKD, driven by a long-term R&D collaboration with Sivea to develop anti-tumor drugs using the AI platform Pharma.AI [1] Group 1: Company Developments - Insilico Medicine has extensive experience in AI-driven tumor drug development and has established a pipeline covering various cancer indications [1] - The company has initiated global multi-center Phase I clinical trials for two drugs: the pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412, with four additional tumor projects licensed out [1] - Insilico's proprietary generative AI platform, Pharma.AI, has incubated over 20 assets in clinical or IND application stages, with three assets licensed to international pharmaceutical companies, totaling a contract value of up to 2.1 billion USD [1] Group 2: Market Performance - As of the latest report, Insilico Medicine's stock is trading at 58.15 HKD with a trading volume of 48.29 million HKD [1] - The company has a strong base of cornerstone investors and is positioned as a leader in the AI drug discovery field [1]
港股异动 | 英矽智能(03696)涨超7%再破顶 公司AI赋能肿瘤药物研发能力再获认可